CD28 and neoplasm: Last, gene modifications developed for CAR-T cell therapies to overcome tumor-related immunosuppression could also be used for TCR-T cells, such as PD-1 disruption, PD-1–CD28 chimeric constructs, or dominant negative transforming growth factor–β receptor type 2 (116).